• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: AIZU OLYMPUS CO., LTD. EVIS EXERA BRONCHOVIDEOSCOPE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

AIZU OLYMPUS CO., LTD. EVIS EXERA BRONCHOVIDEOSCOPE Back to Search Results
Model Number BF-1T160
Medical Device Problem Code Adverse Event Without Identified Device or Use Problem (2993)
Health Effect - Clinical Codes Hemorrhage/Blood Loss/Bleeding (1888); Pneumonia (2011); Pneumothorax (2012); Respiratory Failure (2484)
Type of Reportable Event Serious Injury
Event or Problem Description
Olympus reviewed a literature titled, "prophylactic epinephrine attenuates severe bleeding in lung transplantation patients undergoing transbronchial lung biopsy: results of the prophet randomized trial." background: severe hemorrhage is an uncommon yet potentially life-threatening complication of transbronchial lung biopsy.Lung transplantation recipients undergo multiple bronchoscopies with biopsy and are considered to be at an increased risk for bleeding from transbronchial biopsy, independent of traditional risk factors.We aimed to evaluate the efficacy and safety of endobronchial administration of prophylactic topical epinephrine in attenuating transbronchial biopsy-related hemorrhage in lung transplant recipients.Methods: the prophylactic epinephrine for the prevention of transbronchial lung biopsy-related bleeding in lung transplant recipients study was a 2-center, randomized, double blind, placebo-controlled clinical trial.Participants undergoing transbronchial lung biopsy were randomized to receive 1:10,000-diluted topical epinephrine vs saline placebo administered prophylactically into the target segmental airway.Bleeding was graded based on a clinical severity scale.The primary efficacy outcome was incidence of severe or very severe hemorrhage.The primary safety outcome was a composite of 3-hours all-cause mortality and an acute cardiovascular event.Results: a total of 66 lung transplantation recipients underwent 100 bronchoscopies during the study period.The primary outcome of severe or very severe hemorrhage occurred in 4 cases (8%) in the prophylactic epinephrine group and in 13 cases (24%) in the control group (p = 0.04).The composite primary safety outcome did not occur in any of the study groups.Conclusions: in lung transplantation recipients undergoing transbronchial lung biopsy, prophylactic administration of 1:10,000-diluted topical epinephrine into the target segmental airway before biopsy.Type of adverse events/number of patients: prophylactic epinephrine group: severe or very severed hemorrhage (4), moderate, sever, or very severe hemorrhage (11); saline control group: severe or very severed hemorrhage (13), moderate, sever, or very severe hemorrhage (24).Two patients in the epinephrine group were admitted for iatrogenic pneumothorax, requiring tube thoracostomy.Two patients in the placebo group were admitted post-bronchoscopy for hypoxemic respiratory failure.B two patients in the epinephrine group were admitted within 48 hours of the procedure; both for hypoxemic respiratory failure, one of which was diagnosed with pneumonia.Two patients in the placebo group were admitted within 48 hours of the procedure; one for a small late pneumothorax which did not require drainage and one for pneumonia and hypoxic respiratory failure, requiring mechanical ventilation.This literature requires three reports.The patient identifiers are as follows: (b)(6).This report is for (b)(6).There is no documented olympus device malfunction.Literature link : https://doi.Org/10.1016/j.Healun.2023.03.007 for additional information.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
EVIS EXERA BRONCHOVIDEOSCOPE
Common Device Name
BRONCHOVIDEOSCOPE
Manufacturer (Section D)
AIZU OLYMPUS CO., LTD.
3-1-1 niiderakita
aizuwakamatsu-shi, fukushima 965-8 520
JA  965-8520
MDR Report Key17912164
Report Number2429304-2023-00323
Device Sequence Number7405572
Product Code EOQ
UDI-Device Identifier07290017652061
UDI-Public07290017652061
Combination Product (Y/N)N
Initial Reporter StateMD
Initial Reporter CountryUS
Number of Events Summarized1
Summary Report (Y/N)N
Serviced by Third Party (Y/N)N
Reporter Type Importer
Initial Reporter Occupation Physician
Type of Report Initial
Report Date (Section B) 10/11/2023
Report Date (Section F) 09/22/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Operator of Device Health Professional
Device Model NumberBF-1T160
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Was the Report Sent to FDA? Yes
Distributor Facility Aware Date09/22/2023
Event Location Hospital
Date Report to Manufacturer09/22/2023
Type of Report(Section G)Thirty-Day
Initial Date Received by Manufacturer Not provided
Initial Report FDA Received Date10/11/2023
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Patient Sequence Number1
Outcome Attributed to Adverse Event Required Intervention; Hospitalization;
Patient SexUnknown
-
-